Gilder Gagnon Howe & Co’s TriSalus Life Sciences TLSI Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.87M	Sell	850,081 -38,434	-4%	-$153K	0.04%	184
2026 Q1	$3.55M	Sell	888,515 -90,508	-9%	-$443K	0.04%	170
2025 Q4	$6.83M	Sell	979,023 -68,036	-6%	-$381K	0.07%	136
2025 Q3	$4.87M	Sell	1,047,059 -45,916	-4%	-$215K	0.05%	153
2025 Q2	$5.96M	Buy	1,092,975 +265,618	+32%	+$1.42M	0.06%	136
2025 Q1	$4.57M	Buy	827,357 +812,937	+5,638%	+$4.33M	0.06%	137
2024 Q4	$72.2K	Sell	14,420 -20	-0.1%	-$85	﹤0.01%	253
2024 Q3	$66.6K	Buy	+14,440	New	+$76.5K	﹤0.01%	249
2022 Q3	–	Sell	-172,864	Closed	-$1.7M	–	257
2022 Q2	$1.7M	Sell	172,864 -679,216	-80%	-$6.67M	0.03%	181
2022 Q1	$8.35M	Buy	852,080 +145,847	+21%	+$1.44M	0.08%	149
2021 Q4	$6.98M	Sell	706,233 -2,786	-0.4%	-$27.7K	0.04%	197
2021 Q3	$7.04M	Buy	+709,019	New	+$6.94M	0.04%	225

Other funds holding TLSI

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

WPC

White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Gilder Gagnon Howe & Co's TLSI Position: Q2 2026 in Review

Gilder Gagnon Howe & Co reduced its TriSalus Life Sciences (TLSI) stake by 4.3% in Q2 2026, selling an estimated $153K and leaving 850,081 shares worth $3.87M. The position accounts for 0.04% of the portfolio, ranked #184.

Gilder Gagnon Howe & Co first reported a position in TLSI in Q3 2021 and has held it in 12 quarters since. The position peaked at $8.35M in Q1 2022. 78 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

Gilder Gagnon Howe & Co held 850,081 shares of TriSalus Life Sciences worth $3.87M as of Q2 2026.
Gilder Gagnon Howe & Co sold 38,434 TriSalus Life Sciences shares in Q2 2026, an estimated $153K.
TriSalus Life Sciences made up 0.04% of Gilder Gagnon Howe & Co's portfolio in Q2 2026, its #184 holding.
Gilder Gagnon Howe & Co first reported a position in TriSalus Life Sciences in Q3 2021 and has held it in 12 quarters since.
Gilder Gagnon Howe & Co's TriSalus Life Sciences position peaked at $8.35M in Q1 2022.
78 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2026, filed 14 Aug 2026.